Evolución de la terminología en esteatosis hepática

Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al; NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023: Jun 24. 78: 1966–1986 doi: 10.1097/HEP.0000000000000520. Epub ahead of print. PMID: 37363821.

Sato-Espinoza K, Chotiprasidhi P, Huaman MR, Díaz-Ferrer J. Update in lean metabolic dysfunction-associated steatotic liver disease. World J Hepatol 2024; 16(3): 452-464 [DOI: 10.4254/wjh.v16.i3.452.

Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55(7):434-8.

Tagle Arróspide M. La misma enfermedad, nomenclatura cambiante. Rev Gastroenterol Perú. 2023;43(4):297-9. doi: 10.47892/rgp.2023.434.1647

Schaffner F, Thaler H. Nonalcoholic fatty liver disease. Prog Liver Dis. 1986;8:283-98.

Fouad Y, Waked I, Bollipo S, Gomaa A, Ajlouni Y, Attia D. What's in a name? Renaming 'NAFLD' to 'MAFLD'. Liver Int. 2020;40(6):1254-61.

Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116(6):1413-9.

Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020;73(1):202-209. doi: 10.1016/j.jhep.2020.03.039.

Hong S, Sun L, Hao Y, Li P, Zhou Y, Liang X, Hu J, Wei H. From NAFLD to MASLD: When metabolic comorbidity matters. Ann Hepatol. 2024 Mar-Apr;29(2):101281. doi: 10.1016/j.aohep.2023.101281. Epub 2023 Dec 21. PMID: 38135250.

Danpanichkul, P.; Ng, C.H.; Muthiah, M.D.; Duangsonk, K.; Yong, J.N.; Tan, D.J.H.; Lim, W.H.; Wong, Z.Y.; Syn, N.; Tsusumi, T.; et al. The silent burden of non-alcoholic fatty liver disease in the elderly: A global burden of disease analysis. Aliment. Pharmacol. Ther. 2023, 58, 1062–1074of Disease Study 2019. J. Clin. Med. 2023, 12, 6456.

Chan WK, Chuah KH, Rajaram RB, Lim LL, Ratnasingam J, Vethakkan SR. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review. J Obes Metab Syndr. 2023 Sep 30;32(3):197-213. doi: 10.7570/jomes23052. Epub 2023 Sep 13. PMID: 37700494; PMCID: PMC10583766.

Solomon, A.; Negrea, M.O.; Cipaian, C.R.; Boicean, A.; Mihaila, R.; Rezi, C.; Cristinescu, B.A.; Berghea-Neamtu, C.S.; Popa, M.L.; Teodoru, M.; et al. Interactions between Metabolic Syndrome, MASLD, and Arterial Stiffening: A Single-Center Cross-Sectional Study. Healthcare 2023, 11, 2696.

Wang, A.Y.; Dhaliwal, J.; Mouzaki, M. Lean non-alcoholic fatty liver disease. Clin. Nutr. 2019, 38, 975–981.

De, A.; Bhagat, N.; Mehta, M.; Taneja, S.; Duseja, A. Metabolic dysfunction-associated steatotic liver disease (MASLD) definition is better than MAFLD criteria for lean patients with NAFLD. J. Hepatol. 2023, 79.